Two giant hexagonal turbine rings locking together in a power station and throwing lime green energy.

NAD+ Dosage: What Trials Used by Route (Oral NR and NMN, IV, Injection, Nasal)

November 2, 2026

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It is not a peptide, and it is not an amino-acid chain at all, so it sits on PeptideBlog only because it is sold, injected and stacked alongside peptides. Two related molecules, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), are precursors the body converts toward NAD+, and they are what most human trials have actually tested, by mouth. This guide keeps every route apart: oral NR, oral NMN, intravenous NAD+, intravenous precursors, subcutaneous or intramuscular injection, nasal and sublingual. The amounts that make sense for one route say nothing about another.

Ask PeptideBlog about any peptide

Quick answer: No NAD+ dose is established for wellness use. In published human trials, oral NR ranged from 100 to 2,000 mg a day and oral NMN from 250 to 1,250 mg a day, with blood NAD rising in nearly every trial and functional benefits inconsistent.[1][2][11][16][19] Published intravenous NAD+ amounts are scattered: 10 mg a day for 7 days in a heart-attack trial, 500 mg for 4 days in a retrospective clinic review, and 750 to 1,000 mg in small pilots.[23][24][25][27] I found no published human trial of subcutaneous, intramuscular or nasal NAD+ itself. Online and clinic figures of 250 to 1,000 mg per IV session and 50 to 100 mg per injection have no traced source. See the NAD+ research entry and the NMN entry.

Figures on this page summarize amounts and schedules reported in published research, regulator documents or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Two giant hexagonal turbine rings locking together in a power station and throwing lime green energy.

Every studied or reported NAD+ amount at a glance

Rows are grouped by route. Oral precursor trials come first because they are the strongest evidence, then intravenous work, then injection and nasal, then what circulates online. Milligrams of NAD+, NR and NMN are different molecules and are not interchangeable.

Swipe the table sideways to see every column.

NAD+, NR and NMN amounts by route
SourcePopulationRouteAmountFrequencyDurationEvidence category
Oral NR: Conze 2019Overweight adultsOral NR chloride100, 300 or 1,000 mg (whole-blood NAD up 22, 51 and 142 percent)Not stated in abstract8 weeksPublished human clinical trial (Tier 1)[1]
Oral NR: 1 g a day trialsAged men; Parkinson’s; older adults with cognitive decline; peripheral artery disease; healthy adultsOral NR1,000 mg a day (artery trial: two 250 mg pills twice daily)Daily14 days to 6 monthsPublished human clinical trial (Tier 1)[3][6][7][8][9]
Oral NR: higher doseObese men (40); middle-aged and older adultsOral NR1,000 mg twice daily (obese men); 500 mg twice daily (crossover)Twice daily12 weeks; 2 x 6 weeksPublished human clinical trial (Tier 1)[2][4][5]
Oral NMN: 250 mg a day trialsPrediabetic women; older men; healthy adults; older diabetic menOral NMN250 mg a dayOnce daily6 to 24 weeksPublished human clinical trial (Tier 1)[11][12][13][14][15]
Oral NMN: dose-ranging80 middle-aged adults; 48 runners; 66 adultsOral NMN300, 600 or 900 mg; 300, 600 or 1,200 mg; 2 x 150 mgOnce daily60 days; 6 weeks; 60 daysPublished human clinical trial (Tier 1)[16][17][18]
Oral NMN: highest studied31 healthy adults; 32 overweight adultsOral NMN1,250 mg once daily; MIB-626 1,000 mg once or twice dailyOnce or twice dailyUp to 4 weeks; 14 daysPublished human clinical trial (Tier 1)[19][20]
Head-to-head precursors65 to 67 healthy adultsOral NR, NMN, nicotinamideNR 1,000 mg, NMN 1,000 mg, nicotinamide 500 mgOnce daily14 daysPublished human clinical trial (Tier 1); open label[9]
IV NAD+: heart-attack trial120 STEMI patientsIntravenous10 mg a dayDaily7 daysPublished human clinical trial (Tier 1)[25]
IV NAD+: pharmacokinetic pilotHealthy menIntravenous3 micromoles per minute for 6 hours (750 mg per a 2026 review)Single infusion6 hoursHuman observational or uncontrolled (Tier 2)[23][27]
IV NAD+: older-adult pilot8 adults aged 70 to 80Intravenous1,000 mgDaily6 daysHuman observational or uncontrolled (Tier 2); via reviews, open label[22][27]
IV NAD+ or NR: clinic reviewNAD n=6, NR n=8, commercial clinicIntravenous500 mg of eitherDaily4 consecutive daysHuman observational or uncontrolled (Tier 2); retrospective[24]
IV NAD+: case reportOne woman with rheumatoid arthritisIntravenous250 mg in 500 mL saline over about 1 hourEvery 2 weeks4 infusionsHuman observational or uncontrolled (Tier 2); one case[26]
IV NAD+: registered pediatric trial180 children, not yet recruitingIntravenous2 or 4 mg/kg a day (caps 100 and 200 mg)Daily, 2 hours or more7 daysRegistered human trial (Tier 2)[30]
SC or IM injected NR (not NAD+)40 adults with fatigue, trial status recruitingSubcutaneous or intramuscular50 or 100 mg of injectable NR3 days in a row, then 3 times a weekAbout 100 daysRegistered human trial (Tier 2)[29]
SC or IM NAD+None identifiedSubcutaneous, intramuscularNo published human trial foundNot applicableNot applicableNot consistently reported
Nasal NAD+None identifiedIntranasalNo published human trial foundNot applicableNot applicableNot consistently reported
Wiki: IV protocolNo trial populationIntravenous250 to 500 mg per session (quick reference 250 to 750 mg)2 sessions a week, then monthly2 to 4 week load; infusions 2 to 4 hoursCommunity, vendor or clinic reported (Tier 6); page contradicts itself, no references[31]
Wiki community: IV loading200 reportsIntravenous250 to 500 mg; high-dose group 500 to 1,000 mg4 to 5 sessions over 2 weeks; high dose weeklyThen monthlyCommunity, vendor or clinic reported (Tier 6)[32]
Wiki community: subcutaneous200 reportsSubcutaneous50 to 100 mg, starting at 25 mg2 to 3 times a week8 to 12 weeksCommunity, vendor or clinic reported (Tier 6)[32]
Vial calculatorNo trial populationSubcutaneous50 mg dose from a 500 mg vial in 2 mL (250 mg/mL)Every other dayAbout 10 doses a vialCommunity, vendor or clinic reported (Tier 6); no studies cited[33]
IV clinic menuNo trial populationIntravenous100, 250, 500, 750 or 1,000 mg optionsNot statedNo fixed duration publishedCommunity, vendor or clinic reported (Tier 6)[34]
Nasal spray education pageNo trial populationIntranasal2 to 10 mg per sprayOnce or twice dailyNot statedCommunity, vendor or clinic reported (Tier 6); unnamed sources[35]

The Martens 2018 amount comes from the full text; its abstract states no dose.[2] The older-adult IV pilot is cited through two 2026 reviews, because I could not locate the primary paper.[22][27]

Where these figures come from

The oral numbers trace straight to trial protocols. The injection numbers mostly do not.

Swipe the table sideways to see every column.

NAD+, nicotinamide riboside and nicotinamide mononucleotide are three different products
NAD+NRNMN
What it isThe coenzyme itselfA precursor (vitamin B3 form)A precursor, one step closer to NAD+
Route with human trialsIntravenous only, small studiesOral, many randomized trialsOral, many randomized trials
Usual trial amount10 mg to 1,000 mg per infusion100 to 2,000 mg a day250 to 1,250 mg a day
Regulatory handleFDA 503A bulks list, Category 1Dietary ingredient; GRAS for NR chlorideFDA letters: not excluded from the supplement definition
Where coveredThis pageThis pageThis page and the NMN entry
  • Oral NR and NMN: every amount in the first rows is a randomized or controlled trial dose.[1][9][11][16][19] The most common figures are 250 mg a day for NMN and 1,000 mg a day for NR.
  • Intravenous NAD+: the published amounts range 100-fold, from 10 mg a day in a heart-attack trial to 1,000 mg a day in a pilot, and no trial compared them.[25][27] The 250 to 1,000 mg menus at wellness clinics match the pilot and retrospective-review scale, not the randomized trial scale.[24][27][34]
  • Subcutaneous 50 to 100 mg: no human trial. The wiki community table is the only protocol I found, and it cites no study.[32] The nearest registered trial gives 50 or 100 mg of injectable NR, not NAD+, so the matching numbers do not make the products equivalent.[29]
  • Nasal: no human trial found. One education page gives 2 to 10 mg per spray and names no source.[35]
  • Websites repeating each other: the wiki IV range contradicts itself within one page (250 to 500 mg in one place, 250 to 750 mg in another, infusions of 2 to 4 hours in one place and 2 to 8 in another).[31] I could not trace either range to a study.
  • Weight-based dosing: only in the registered pediatric trial (2 and 4 mg/kg), which has not started enrolling.[30]

The units guide covers milligram, microgram and syringe-mark mix-ups, and the routes guide explains why route changes everything.

Whole-blood NAD rise by oral NR dose over 8 weeksBar chart. Nicotinamide riboside at 100 milligrams raised whole-blood NAD by 22 percent, 300 milligrams by 51 percent and 1,000 milligrams by 142 percent in overweight adults over 8 weeks.0%50%100%150%Rise in whole-blood NAD (percent)22%100 mgNR51%300 mgNR142%1,000 mgNR
Conze 2019, 8-week randomized trial. A blood NAD rise shows the precursor was absorbed and converted. It does not show a health benefit.

Detailed human data by route

Oral NR

Swipe the table sideways to see every column.

Oral NR in human trials
Research objectiveAmount studiedFrequencyDurationRouteStudy populationFindings and limits
Dose response of blood NAD (Conze 2019)100, 300, 1,000 mgNot stated in abstract8 weeksOralOverweight adultsNAD up 22, 51, 142 percent; no flushing; adverse events similar to placebo[1]
Tolerability and NAD (Martens 2018)500 mg twice dailyTwice daily2 x 6 weeks, crossoverOralMiddle-aged and older adultsWell tolerated; raised NAD metabolism[2]
Muscle NAD (Elhassan 2019)1 g a dayDaily21 days, crossoverOral12 aged menRaised muscle NAD metabolome; lower inflammatory cytokines; no change in mitochondrial bioenergetics[3]
Insulin sensitivity (Dollerup 2018, 2019)1,000 mg twice dailyTwice daily12 weeksOral40 obese, insulin-resistant menNo improvement in insulin sensitivity, body composition, incretins or beta-cell function[4][5]
Parkinson’s (NADPARK 2022)1,000 mgDaily30 daysOral30 newly diagnosed patientsBrain NAD rose, variably; mild clinical improvement in those with a rise; phase 1[6]
Peripheral artery disease (NICE 2024)1,000 mg a day (two 250 mg pills, twice daily)Twice daily6 monthsOral90 patients6-minute walk +7.0 m versus -10.6 m placebo; difference +17.6 m, 90 percent CI +1.8 to infinity[7]
Cognition (Wu 2025)1 g a dayDaily8 weeks, crossoverOral46 randomized, 37 finishedPlasma pTau217 -7 percent versus +18 percent (p=0.02); no cognition difference[8]

Oral NMN

Swipe the table sideways to see every column.

Oral NMN in human trials
Research objectiveAmount studiedFrequencyDurationRouteStudy populationFindings and limits
Insulin sensitivity (Yoshino 2021)250 mg a dayOnce daily10 weeksOral25 prediabetic postmenopausal women finished (12 placebo, 13 NMN)Muscle insulin sensitivity and signaling improved[11]
Blood NAD in older men (Igarashi 2022)250 mg a dayOnce daily6 or 12 weeksOralOlder menBlood NAD rose; gait speed and grip changes nominal only[12]
Safety and NAD (Okabe 2022)250 mg a dayOnce daily12 weeksOral30 healthy subjectsWhole-blood NAD rose; no abnormalities[13]
Time of day (Kim 2022)250 mgOnce daily, morning or afternoon12 weeksOral108 older adultsAfternoon dose improved sit-to-stand and drowsiness more[14]
Older diabetic men (Akasaka 2022)250 mg a dayDaily24 weeksOral14 men, mean age 81No gain in grip strength or walking speed[15]
Dose response (Yi 2022)300, 600, 900 mgOnce daily60 daysOral80 middle-aged adultsBlood NAD highest at 600 and 900 mg; well tolerated[16]
NAD and insulin resistance (Huang 2022)2 x 150 mgOnce daily after breakfast60 daysOral66 adults aged 40 to 65Serum NAD/NADH up 38 percent versus 14.3 percent placebo; a branded-product trial[17]
Aerobic capacity (Liao 2021)300, 600, 1,200 mg a dayDaily6 weeksOral48 amateur runnersOxygen uptake rose more in the 600 and 1,200 mg groups[18]
Safety at high dose (Fukamizu 2022)1,250 mgOnce dailyUp to 4 weeksOral31 healthy adultsNo severe adverse events[19]
Pharmacokinetics (Pencina 2023, MIB-626)1,000 mgOnce or twice daily14 daysOral32 overweight adults aged 55 to 80Dose-related rises in blood NAD[20]

Reading across: NR and NMN reliably raise blood NAD, and in the one head-to-head trial NR and NMN at 1,000 mg a day did so comparably while nicotinamide did not.[9] The study abstract says 65 healthy participants, while the full text says 67 enrolled.[9] Functional results are mixed. A 2025 meta-analysis found no significant muscle effects of NMN, and a 2026 systematic review of 33 human intervention studies called effectiveness for anti-aging or wellness outcomes inconclusive.[21][22] The Freeberg blood-pressure trial of NR 500 mg twice daily for 3 months is registered (NCT03821623) and not yet reported.[10]

Intravenous NAD+ and precursors

Swipe the table sideways to see every column.

Intravenous NAD+ in humans
Research objectiveAmount studiedFrequencyDurationRouteStudy populationFindings and limits
Fate of infused NAD+ (Grant 2019)3 micromoles per minuteSingle infusion6 hoursIntravenousHealthy men; 8 on NAD (750 mg) and 3 on saline per a 2026 reviewPlasma NAD+ was cleared completely for the first 2 hours; urinary metabolites rose by 6 hours[23][27]
Older-adult pilot (Braidy 2018)1,000 mgDaily6 daysIntravenous8 adults aged 70 to 80, open labelCited through reviews only; primary paper not located[22][27]
Tolerability (Reyna 2026)500 mg NAD or NRDaily4 days, 30 day follow-upIntravenousNAD n=6, NR n=8, clinic clientsNAD: GI symptoms, faster heart rate, chest pressure; infusions averaged 97 min versus 37 min for NR; retrospective, authors affiliated with a wellness provider[24]
Heart function after STEMI (2026)10 mg a dayDaily7 daysIntravenous120 patients, randomized, placebo controlledLVEF at 30 days 56.32 percent versus 53.37 percent (p=0.048); no difference in 6-month cardiac events[25]
Rheumatoid arthritis (case report)250 mg in 500 mL salineEvery 2 weeks4 infusions of about 1 hourIntravenousOne 49-year-old womanTemporal improvement only; authors say causation cannot be inferred[26]

A 2026 narrative review summarizes the field as sparse, mostly small uncontrolled studies, observational work and case reports, and a 2026 systematic review found no eligible outcome trials of IV or IM NAD+ for anti-aging or wellness.[22][27] The review also describes a Parkinson’s case report (1,500 mg for 2 days, then 500 to 750 mg for 4 days) and an IV NMN safety study in 10 volunteers, neither of which I could read at source.[27] The wiki quotes 500 to 1,000 mg daily for 7 to 10 days as an “intensive” protocol; the Parkinson’s case and the older-adult pilot are the nearest published scale.[27][31]

Subcutaneous, intramuscular, nasal and sublingual

For NAD+ itself, I found no published human trial by any of these routes. The closest registered work is a 40-person safety pilot of an injectable NR product (50 or 100 mg, subcutaneous or intramuscular; three daily injections, then home self-injection three times a week through about day 100), sponsored by an NR manufacturer. The registry lists it as recruiting although its stated completion date was February 2026, and it has no results.[29] A second registered trial is the PEDI-NAD pediatric protocol above, which uses an approved-in-China “Coenzyme I” product supplied in 5 mg vials, indicated per the registry for coronary heart disease and myocarditis, and given intravenously at 1.6 mg/mL.[30]

Animal research amounts

These are per-kilogram amounts from one 2026 GLP-compliant study of intramuscular NAD+. They are not convertible to human amounts and I have not tried.[28]

Swipe the table sideways to see every column.

NAD+ in animal safety studies
Research objectiveSpecies or modelAmount studiedFrequencyDurationRouteFindings
Safety pharmacologyBeagle dogs3 to 30 mg/kgSingle doseSingleIntramuscular3 mg/kg safe; 10 and 30 mg/kg raised heart rate, shortened PR and QT intervals, lowered blood pressure[28]
Acute toxicityRats45 to 180 mg/kgSingle doseSingleIntramuscularMaximum tolerated dose at least 180 mg/kg[28]
Repeated-dose toxicityRats10 to 100 mg/kgOnce daily4 weeks plus 4 week recoveryIntramuscularNo-effect level 100 mg/kg; injection-site and sciatic-nerve lesions reversible[28]
Muscle irritation, hemolysis, anaphylaxisRabbits, rabbit red cells, guinea pigsNot given in abstract14 consecutive days (rabbits)14 daysIntramuscular, in vitro, IV challengeAll negative[28]

It is the only animal study of injected NAD+ I read, and I read the abstract only. I did not survey the wider rodent literature on NR or NMN, which is large and not directly tied to the amounts people take.[22][28]

Practitioner and community protocols

These are the figures people search for. None is clinical evidence, and the wiki labels its own NAD+ dosing page “unverified.”[31]

Swipe the table sideways to see every column.

Practitioner, clinic and community NAD+ protocols as the sources state them
ProtocolAmount reportedRouteFrequencyDuration and notesSource and dateSource type
IV standard250 to 500 mg per session (quick reference 250 to 750 mg)Intravenous2 sessions a week for a 2 to 4 week load, then monthlyInfusions 2 to 4 hours (quick reference 2 to 8); start 1 to 2 mg/minPeptide Protocol Wiki, dosing page, Feb 2026; no citations[31]Wiki
IV intensive500 to 1,000 mg dailyIntravenousDaily7 to 10 days over 4 to 8 hoursSame page, neuro and addiction protocols[31]Wiki
IV loading, community250 to 500 mg; some 500 to 1,000 mg weeklyIntravenous4 to 5 sessions over 2 weeks, then monthlyHigh-dose: weekly for 4 weeks, then monthlyWiki community page, Feb 2026, 200 reports; effects named: flushing, chest tightness, nausea, cramping, anxiety-like sensations with fast infusion[32]Community
Subcutaneous50 to 100 mg, starting at 25 mgSubcutaneous2 to 3 times a week8 to 12 weeks; titration 25 mg weeks 1 to 2, 50 mg weeks 3 to 4, 100 mg from week 5, twice weeklySame community page[32]Community
Vial arithmetic example50 mg per doseSubcutaneousEvery other dayAbout 10 doses per 500 mg vial; use within 28 days refrigeratedWiki calculator: 500 mg in 2 mL = 250 mg/mL, 20 units on a U-100 syringe = 0.2 mL[33]Wiki
Sublingual50 to 200 mg a daySublingualDailyNot statedWiki dosing page[31]Wiki
Oral precursors, wikiNR 300 mg standard (500 to 1,000 mg in trials, 2,000 mg maximum studied); NMN 250 to 500 mg (up to 1,250 mg in trials)OralDailyNot statedWiki dosing page; the trial figures match the published trials above[31]Wiki
IV menu100, 250, 500, 750, 1,000 mgIntravenousNot statedNo fixed time published; lists nausea, flushing, abdominal discomfort, chest tightness if infused too fastIV wellness clinic menu, Jul 2026 (clinic described by type; not named)[34]Clinic
Nasal2 to 10 mg per sprayIntranasalOnce or twice dailyNot statedSubscription-health education page, Oct 2025, unnamed sources[35]Company education

If you are converting the calculator example: 20 units on a U-100 syringe is 0.2 mL only when the concentration is known, here 250 mg/mL.[33] The reconstitution calculator and the reconstitution guide show the arithmetic. I could not open Reddit, so no forum thread is quoted.

Two glowing hexagonal turbine rings locking together and releasing yellow green energy in a power station

Escalation, timing, duration, routes

  • Infusion rate matters: the pharmacokinetic pilot ran at 3 micromoles per minute for 6 hours, and a clinic review found NAD infusions at 500 mg took 97 minutes on average because symptoms forced slowdowns, against 37 minutes for NR.[23][24] The wiki suggests starting at 1 to 2 mg/min.[31]
  • Oral dose response: blood NAD rose with dose in the NR trial up to 1,000 mg, and in the NMN trial it was highest at 600 and 900 mg a day.[1][16]
  • Time of day: one NMN trial found afternoon dosing improved sit-to-stand and drowsiness more than morning dosing.[14]
  • Duration: oral trials run 14 days to 6 months; the longest was 6 months for NR in artery disease.[7] No trial runs a multi-year protocol.
  • Routes: oral NR and NMN, IV NAD+ and precursors, and registered SC or IM injection of NR. A 2026 review of IV therapy notes that recent large-scale human data indicate whole-blood NAD does not decline with healthy aging, which complicates the common rationale of replacing what age removes.[27]

Combinations and stacks

Formally studied: NR with resveratrol in peripheral artery disease; resveratrol added no benefit over NR alone.[7] Mechanistically plausible: pairing NAD+ with MOTS-c or 5-amino-1MQ; I found no trial of either combination, and the NAD+, MOTS-c and 5-amino-1MQ blend entry covers what the name refers to. Community and clinic reported: I did not trace a sourced combined protocol with glutathione, urolithin A or any other add-on, so none is tabled. Popularity is not evidence. See also the longevity area and adjunct area.

Side effects, quality and sourcing risks as reported

Oral precursors: NR at 100 to 1,000 mg had no more adverse events than placebo and no flushing in the dose-response trial, and NMN at 1,250 mg a day for up to 4 weeks produced no severe adverse events.[1][19] The trials are short, and no one has tested years of use.[22] The Parkinson’s trial described NR as well tolerated.[6]

Intravenous NAD+: in the clinic review, 500 mg of NAD caused moderate to severe GI symptoms, increased heart rate and chest pressure during infusion, resolved after stopping; NR IV caused mild tingling and cramping.[24] The wiki and clinic menus list flushing, chest tightness, nausea and cramping with fast infusion.[32][34] In dogs, higher intramuscular NAD+ amounts raised heart rate and shortened ECG intervals, a finding that is not translated to people here.[28] The heart-attack trial reported no 6-month difference in cardiac events and the abstract does not state adverse events.[25]

Quality: the registry text for the pediatric trial describes the injectable as a marketed product with a national approval number, 5 mg per vial, stored at or below 20 C.[30] Products sold for wellness injection may differ in form, strength and sterility, and a seller’s certificate is its own claim; the COA guide explains what it can show. I found no independent testing study of commercial NAD+ vials.

Regulatory status

As of 2 November 2026, in the sources I could open:

  • NAD+ injectable: I found no FDA-approved NAD+ injectable product. FDA’s 503A bulk-substance list, updated 14 May 2026, shows “Nicotinamide Adenine Dinucleotide (NAD)” and the reduced disodium form in Category 1, and the beta-NAD disodium salt trihydrate in Category 3.[36] FDA says that for Category 1 substances it does not intend to take action against a compounder who meets the interim-policy conditions.[37] That is enforcement discretion for compounding, not approval of a dose, indication or product.
  • HHS October 2026 peptide policy: the HHS policy and Federal Register notice on peptide compounding do not mention NAD, because NAD+ is not a peptide. Its conditions apply to the listed peptides, not here.[38][39] The HHS policy post and the FDA peptide status page cover the peptide side.
  • NMN: FDA letters dated 29 September 2025 said NMN is not excluded from the definition of a dietary supplement, and letters of 2 December 2025 repeated that. It remains a new dietary ingredient needing premarket notification, and the FDA position reflects its current thinking.[40][41]
  • NR: NR chloride is generally recognized as safe for food use and has two new dietary ingredient notifications.[1]
  • Elsewhere: an injectable “Coenzyme I” with a national approval number is marketed in China for coronary heart disease and myocarditis, per the pediatric trial registry.[30] I did not research other countries.
Interlocking hexagonal turbines releasing yellow green energy along steel catwalks in a power station

What is not public

  • Any randomized trial of IV NAD+ at wellness doses (250 to 1,000 mg) for any wellness outcome.[22]
  • Any human trial of subcutaneous, intramuscular, nasal or sublingual NAD+.
  • Pharmacokinetics for injected NAD+ other than the 6-hour pilot.[23]
  • A source for the wiki IV, subcutaneous and sublingual ranges.[31][32]
  • Long-term safety of any route, and results of the registered NR injection and pediatric NAD+ trials.[29][30]
  • The full text of the older-adult IV pilot, the Parkinson’s case and the IV NMN safety study, which are cited here only through reviews.[22][27]

Frequently asked questions

Is NAD+ a peptide?

No. NAD+ is a coenzyme, a small molecule built from two nucleotides, not a chain of amino acids. It appears next to peptides because it is sold through the same channels. NR and NMN are separate precursors.[22][27]

What dose of NR and NMN has been studied in humans?

Oral NR from 100 to 1,000 mg a day in trials, with 2,000 mg a day in one obese-men trial of 1,000 mg twice daily. Oral NMN from 250 mg a day up to 1,250 mg a day for 4 weeks. Blood NAD rose; benefits beyond that were inconsistent.[1][4][11][16][19]

How much IV NAD+ is reported?

Published human work includes 10 mg a day for 7 days (heart attack trial), 500 mg for 4 days (clinic review), 250 mg infusions (case report) and 750 to 1,000 mg in pilots. Wellness clinics list 100 to 1,000 mg per session.[24][25][26][27][34]

Has subcutaneous NAD+ been studied in humans?

I found no published human trial of subcutaneous or intramuscular NAD+. A registered trial is testing injectable NR at 50 or 100 mg, which is a different product.[29]

Is nasal or sublingual NAD+ studied?

I found no published human trial for either route. Online amounts such as 2 to 10 mg per spray or 50 to 200 mg sublingually come from education pages without sources.[31][35]

Do NR and NMN actually raise NAD+?

They raise whole-blood NAD in most trials. In a 14-day head-to-head study, NR and NMN at 1,000 mg a day did so comparably and nicotinamide did not. Whether that translates to better health is inconsistent, and a 2025 meta-analysis found no significant NMN effects on muscle.[9][21]

What side effects are reported with IV NAD+?

In a clinic review, 500 mg of NAD caused GI symptoms, faster heart rate and chest pressure, and slowed the infusion. Wiki and clinic lists add flushing, cramping and nausea with fast infusion.[24][32][34]

Is NAD+ FDA approved or legal to compound?

I found no FDA-approved NAD+ injectable. FDA lists NAD in Category 1 of its 503A bulks list, which means it does not intend to act against compounders who meet the conditions. NMN is lawful as a supplement per FDA letters.[36][37][40]

How is a NAD+ vial reconstituted?

No label sets a method here. The wiki example is 500 mg in 2 mL for 250 mg/mL. The reconstitution calculator shows the arithmetic once strength and volume are known.[33]

Bottom line

NAD+ is a real, essential coenzyme, and raising blood NAD with oral NR or NMN is well documented at 100 to 2,000 mg a day for NR and 250 to 1,250 mg a day for NMN.[1][11][19] What is genuinely published for injections is thin: a few small intravenous studies at very different amounts, from 10 mg to 1,000 mg, with a clinic review suggesting tolerability depends on infusion speed.[23][24][25] What is merely reported online: IV sessions of 250 to 1,000 mg, subcutaneous 50 to 100 mg, sublingual 50 to 200 mg and nasal sprays, none of which traces to a trial.[31][32][35] What stays speculative: anti-aging, energy and longevity claims for injected NAD+. FDA lists NAD in Category 1 of its 503A bulks list, which is enforcement discretion and not approval. See the evidence standards for the tiers and the sister page on epitalon dosage.

Keep reading

Sources

  1. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. https://doi.org/10.1038/s41598-019-46120-z PMID 31278280. Published human clinical trial (Tier 1)
  2. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. https://doi.org/10.1038/s41467-018-03421-7 PMID 29599478. Published human clinical trial (Tier 1)
  3. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-1728. https://doi.org/10.1016/j.celrep.2019.07.043 PMID 31412242. Published human clinical trial (Tier 1)
  4. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Am J Clin Nutr. 2018;108(2):343-353. https://doi.org/10.1093/ajcn/nqy132 PMID 29992272. Published human clinical trial (Tier 1)
  5. Dollerup OL, Trammell SAJ, Hartmann B, et al. Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity. J Clin Endocrinol Metab. 2019;104(11):5703-5714. https://doi.org/10.1210/jc.2019-01081 PMID 31390002. Published human clinical trial (Tier 1)
  6. Brakedal B, Dolle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 2022;34(3):396-407. https://doi.org/10.1016/j.cmet.2022.02.001 PMID 35235774. Published human clinical trial (Tier 1)
  7. McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15:5046. https://doi.org/10.1038/s41467-024-49092-5 PMID 38871717. Published human clinical trial (Tier 1)
  8. Wu CY, Kupferschmid AC, Chen L, et al. Cognitive and Alzheimer’s disease biomarker effects of oral nicotinamide riboside supplementation in older adults. Alzheimers Dement (N Y). 2025;11:e70023. https://doi.org/10.1002/trc2.70023 PMID 39817194. Published human clinical trial (Tier 1) (small crossover)
  9. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8:62-73. https://doi.org/10.1038/s42255-025-01421-8 PMID 41540253. ClinicalTrials.gov NCT05517122. Published human clinical trial (Tier 1) (open label)
  10. Freeberg KA, Craighead DH, Martens CR, et al. Nicotinamide riboside supplementation for treating elevated systolic blood pressure and arterial stiffness in midlife and older adults (protocol). Front Cardiovasc Med. 2022;9:881703. https://doi.org/10.3389/fcvm.2022.881703 PMID 35620522. NCT03821623. Registered human trial (Tier 2) (protocol; results not published)
  11. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-1229. https://doi.org/10.1126/science.abe9985 PMID 33888596. Published human clinical trial (Tier 1)
  12. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. NPJ Aging. 2022;8:5. https://doi.org/10.1038/s41514-022-00084-z PMID 35927255. Published human clinical trial (Tier 1)
  13. Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood NAD+ levels in healthy subjects. Front Nutr. 2022;9:868640. https://doi.org/10.3389/fnut.2022.868640 PMID 35479740. Published human clinical trial (Tier 1)
  14. Kim M, Seol J, Sato T, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients. 2022;14(4):755. https://doi.org/10.3390/nu14040755 PMID 35215405. Published human clinical trial (Tier 1)
  15. Akasaka H, Nakagami H, Sugimoto K, et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance. Geriatr Gerontol Int. 2023;23(1):38-43. https://doi.org/10.1111/ggi.14513 PMID 36443648. Published human clinical trial (Tier 1)
  16. Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. https://doi.org/10.1007/s11357-022-00705-1 PMID 36482258. Published human clinical trial (Tier 1)
  17. Huang H. A multicentre, randomised, double blind, parallel design, placebo controlled study to evaluate the efficacy and safety of Uthever (NMN supplement) in middle aged and older adults. Front Aging. 2022;3:851698. https://doi.org/10.3389/fragi.2022.851698 PMID 35821806. NCT04228640. Published human clinical trial (Tier 1); product trial, single author
  18. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18:54. https://doi.org/10.1186/s12970-021-00442-4 PMID 34238308. Published human clinical trial (Tier 1)
  19. Fukamizu Y, Uchida Y, Shigekawa A, et al. Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12:14442. https://doi.org/10.1038/s41598-022-18272-y PMID 36002548. Published human clinical trial (Tier 1)
  20. Pencina KM, Lavu S, Dos Santos M, et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, increases circulating NAD and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. https://doi.org/10.1093/gerona/glac049 PMID 35182418. Published human clinical trial (Tier 1)
  21. Prokopidis K, Moriarty F, Bahat G, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025;16(3):e13799. https://doi.org/10.1002/jcsm.13799 PMID 40275690. Meta-analysis (secondary)
  22. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. https://doi.org/10.1016/j.arr.2026.103057 PMID 41655607. Systematic review (secondary)
  23. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. https://doi.org/10.3389/fnagi.2019.00257 PMID 31572171. Human observational or uncontrolled (Tier 2)
  24. Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of NAD versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. https://doi.org/10.3389/fragi.2026.1652582 PMID 41704678. Human observational or uncontrolled (Tier 2); authors affiliated with a wellness provider
  25. Yu X, Cao J, Xu Q, et al. Effect of intravenous nicotinamide adenine dinucleotide on left ventricular function after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: a randomized controlled trial. Am J Cardiovasc Drugs. 2026. https://doi.org/10.1007/s40256-026-00826-4 PMID 42961639. ChiCTR2200059333. Published human clinical trial (Tier 1)
  26. Itani MR, Farhat A, Abou Yehya N, et al. Symptomatic and ultrasonographic improvement in rheumatoid arthritis temporally associated with intravenous NAD+ therapy: a case report. ACR Open Rheumatol. 2026;8(9):e90151. https://doi.org/10.1002/acr2.90151 PMID 42751848. Case report
  27. Alangari A, Arif J, Al Qureshah F, Alkhodairy F. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging. 2026;7:1887175. https://doi.org/10.3389/fragi.2026.1887175 PMID 42787547. Narrative review (secondary); source for several amounts whose primary papers I could not open
  28. Gu J, Xu J, Yang S, et al. Non-clinical safety evaluation of coenzyme I (NAD+): a GLP-compliant systematic study. Biomed Pharmacother. 2026;204:119934. https://doi.org/10.1016/j.biopha.2026.119934 PMID 42748828. Published animal research (Tier 3)
  29. ClinicalTrials.gov NCT07251608. Randomized, open-label, safety study of subcutaneous and intramuscular injections of a branded injectable nicotinamide riboside (sponsor is an NR manufacturer; name held by the editor). https://clinicaltrials.gov/study/NCT07251608 Registered human trial (Tier 2); NR, not NAD+
  30. ClinicalTrials.gov NCT07839130. The PEDI-NAD trial: injectable nicotinamide adenine dinucleotide for pediatric cardiac dysfunction. Sponsor: Beijing Children’s Hospital. https://clinicaltrials.gov/study/NCT07839130 Registered human trial (Tier 2)
  31. Peptide Protocol Wiki Team. NAD+: dosing protocols. Page updated 12 February 2026. https://www.peptideprotocolwiki.com/peptides/nad-plus/dosing Community, vendor or clinic reported (Tier 6). Labeled “unverified”; no citations.
  32. Peptide Protocol Wiki Team. NAD+: community protocols and reports. Page updated 16 February 2026. https://www.peptideprotocolwiki.com/peptides/nad-plus/community Community, vendor or clinic reported (Tier 6). 200 reports.
  33. Peptide Protocol Wiki. NAD+ 500 mg vial dosing calculator (undated). https://www.peptideprotocolwiki.com/tools/dosing-calculator/nad-plus-500mg Community, vendor or clinic reported (Tier 6). No studies cited.
  34. IV wellness clinic menu page for NAD+ infusions, 28 July 2026 (clinic sells the service; address held by the editor and not linked on purpose). Community, vendor or clinic reported (Tier 6)
  35. Subscription-health company education page on intranasal NAD+, 18 October 2025 (address held by the editor and not linked on purpose). Community, vendor or clinic reported (Tier 6)
  36. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (Categories 1, 2 and 3). Updated 14 May 2026. https://www.fda.gov/media/94155/download Regulator document
  37. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act. Content current as of 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act Regulator document
  38. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and B (PDF), October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Regulator document
  39. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register document 2026-22192, docket HHS-OASH-2026-0496, public inspection 28 October 2026. https://public-inspection.federalregister.gov/2026-22192.pdf Regulator document
  40. Venable LLP. FDA declares nicotinamide mononucleotide is lawful in dietary supplements. 2 October 2025. https://www.venable.com/insights/publications/2025/10/fda-declares-nicotinamide-mononucleotide-is Law-firm summary of FDA letters (secondary)
  41. NutraIngredients. FDA reinstates NDI status of NMN with new letters to ingredient players. 9 December 2025. https://www.nutraingredients.com/Article/2025/12/09/fda-reinstates-ndi-status-of-nmn-with-new-letters-to-ingredient-players Trade press (secondary)

Educational reference only, not medical advice. This page documents amounts in published research, regulator documents and figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.

Share thisFacebookXEmail
Image placeholder

PeptideBlog Editorial compiles and reviews published research, clinical trial data, and community-reported information on peptides so readers can see what is actually documented versus what is simply repeated online. Every entry is sourced and evidence-graded. This is educational content, not medical advice.